STRIDE validated in human in vivo samples in collaboration with AstraZeneca
In collaboration with AstraZeneca, intoDNA has validated STRIDE as a groundbreaking tool for quantification of DNA breaks in different types of human clinical samples.
Share your details with us and we will deliver the case study Development and validation of a customized, functional STRIDE-based assay to measure Mismatch Repair (MMR) pathway activity in cells to your inbox.
Share your details with us and we will deliver the case study Studying the effects of alpha and beta-emitters alone and in combination with a DDR inhibitor in a human cell line model to your inbox.
Share your details with us and we will deliver the case study Studying the MoA of a DDR inhibitor in Patient-Derived Xenograft (PDX) models using STRIDE to your inbox.
Download the AACR poster launching the novel sSTRIDE-SMUG1 assay
Share your details with us and we will deliver the poster Measuring the activity of SMUG1 DNA glycosylase with a novel sSTRIDE-SMUG1 assay to your inbox.
Download the AACR poster on the potential of dSTRIDE-HR assays to become predictive biomarkers in breast tumors with HR-deficiencies.
Share your details with us and we will deliver the poster Novel dSTRIDE-HR assays can accurately assess DNA repair defects in human cancers and distinguish HR status of tumors to your inbox.